YYÜ GCRIS Basic veritabanının içerik oluşturulması ve kurulumu Research Ecosystems (https://www.researchecosystems.com) tarafından devam etmektedir. Bu süreçte gördüğünüz verilerde eksikler olabilir.
 

The Use of Recombinant Factor Viia in a Child With Glanzmann Thrombasthenia

dc.authorscopusid 8930720100
dc.authorscopusid 7005791514
dc.authorscopusid 56208434400
dc.authorscopusid 14526773500
dc.contributor.author Bay, A.
dc.contributor.author Öner, A.F.
dc.contributor.author Çankaya, H.
dc.contributor.author Doǧan, M.
dc.date.accessioned 2025-05-10T17:51:17Z
dc.date.available 2025-05-10T17:51:17Z
dc.date.issued 2006
dc.department T.C. Van Yüzüncü Yıl Üniversitesi en_US
dc.department-temp Bay A., Yüzüncü Yil Üniversitesi, Tip Fakültesi, Pediatri Anabilim Dali, Van, Turkey, Yüzüncü Yil Üniversitesi, Tip Fakültesi, Pediatri Anabilim Dali, 65300 Van, Maraş Caddesi, Turkey; Öner A.F., Yüzüncü Yil Üniversitesi, Tip Fakültesi, Pediatri Anabilim Dali, Van, Turkey; Çankaya H., Yüzüncü Yil Üniversitesi, Tip Fakültesi, Kulak Burun Boǧaz Hastaliklari Anabilim Dali, Van, Turkey; Doǧan M., Yüzüncü Yil Üniversitesi, Tip Fakültesi, Pediatri Anabilim Dali, Van, Turkey en_US
dc.description.abstract Glanzmann thrombasthenia is an autosomal recessive disorder of platelet aggregation that is characterized by a life-long bleeding tendency due to quantitative and qualitative abnormalities of the platelet membrane complex glycoprotein IIb/IIIa (Gp IIb/IIIa). Platelet transfusion is the standard treatment for severe bleeding and surgical support is necessary in these patients. However, repeated platelet transfusions can result in alloimmunization, which makes subsequent transfusions ineffective. Recombinant activated factor VIIa (rFVIIa) has recently been introduced as an alternative to platelet transfusion for treatment of bleeding episodes and to cover surgery in patients with hereditary platelet function defects. We report a 8-year-old child with Glanzmann thrombasthenia. The patient had been treated by nasal tampon placement because of epistaxis three years ago in another hospital. We detected perforation of nasal septum and deformation of nasal bone due to granulation tissue induced by forgotten nasal tampon. Forgotten tampon was removed and granulation tissue was resected. Bolus injections of rFVIIa (90 _g/kg) was given immediately before operation and three times with 2 hours intervals after the surgery. The patient was discharged from hospital without any bleeding complication or thrombocyte replacement. en_US
dc.identifier.endpage 89 en_US
dc.identifier.issn 1306-133X
dc.identifier.issue 2 en_US
dc.identifier.scopus 2-s2.0-33745749821
dc.identifier.scopusquality Q4
dc.identifier.startpage 87 en_US
dc.identifier.trdizinid 59996
dc.identifier.uri https://hdl.handle.net/20.500.14720/18066
dc.identifier.volume 16 en_US
dc.identifier.wosquality Q4
dc.language.iso en en_US
dc.relation.ispartof UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Child en_US
dc.subject Glanzmann Thrombasthenia en_US
dc.subject Recombinant Activated Factor Viia en_US
dc.title The Use of Recombinant Factor Viia in a Child With Glanzmann Thrombasthenia en_US
dc.type Article en_US

Files